RxDoctor Payments Data

Kenneth Bauer, MD

Hematology & Oncology · West Roxbury, MANPI 1558309849

Payments from drug & device makers

$74,041in general payments, 2019–2025

Across 78 payments — averaging $949.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$33K
  • E.r. Squibb & Sons, L.L.C.$15K
  • Abbott$7K
  • Takeda Pharmaceuticals U.S.A., Inc.$6K
  • Janssen Research & Development, LLC$5K
  • Biomarin Pharmaceutical Inc.$2K
  • plus $7K from 13 others

What the payments were for

  • Consulting fees$65,02388%
  • Speaking & faculty fees$2,4503%
  • Travel & lodging$2,8054%
  • Food & beverage$3,7635%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$74,041 in reported general payments places this provider in the 60th percentile of 374 hematology & oncology providers in Massachusetts.

See all hematology & oncology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$27,217
Medicare patients
145
Services billed
214

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PromactaEltrombopag Olamine15$224,693
EliquisApixaban101$135,036
XareltoRivaroxaban66$90,103
Fondaparinux Sodium14$25,702
Enoxaparin Sodium14$4,056
Hydroxyurea68$2,584
Warfarin Sodium28$459

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$93$90,10366 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 374 hematology & oncology providers in Massachusetts.

Other hematology & oncology in West Roxbury

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →